[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O: Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer; 2009 Dec 15;101(12):1978-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial.
  • At this stage, anti-cancer treatments aim at relieving symptoms and delaying death without resulting in additional toxicity.
  • On the basis of their differential anti-oxidant defence level, tumour cells can be made more sensitive to chemotherapy than non-tumour cells when membrane lipids are enriched with docosahexaenoic acid (DHA), a peroxidisable and oxidative-stress-inducing lipid of marine origin.
  • METHODS: This open-label single-arm phase II study evaluated the safety and efficacy (response rate), as primary end points, of the addition of 1.8 g DHA daily to an anthracycline-based chemotherapy (FEC) regimen in breast cancer patients (n = 25) with rapidly progressing visceral metastases.
  • The secondary end points were time to progression (TTP) and overall survival (OS).
  • With a mean follow-up time of 31 months (range 2-96 months), the median TTP was 6 months.
  • Median OS was 22 months and reached 34 months in the sub-population of patients (n = 12) with the highest plasma DHA incorporation.
  • CONCLUSION: DHA during chemotherapy was devoid of adverse side effects and can improve the outcome of chemotherapy when highly incorporated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Docosahexaenoic Acids / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Cancer. 2007;58(2):230-8 [17640170.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5879-86 [17020996.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Mar;35(3):437-40 [18347392.001]
  • [Cites] Free Radic Biol Med. 2008 Apr 1;44(7):1483-91 [18267129.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4294-300 [19401447.001]
  • [Cites] Eur J Cancer. 2000 May;36(8):966-75 [10885599.001]
  • [Cites] Mol Cell Biochem. 2000 Apr;207(1-2):77-86 [10888230.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3115-24 [10963640.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):2041-9 [11448922.001]
  • [Cites] J Mol Neurosci. 2001 Apr-Jun;16(2-3):201-4; discussion 215-21 [11478375.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):169-77 [12359365.001]
  • [Cites] Pharmacol Res. 2003 Feb;47(2):111-7 [12543058.001]
  • [Cites] J Chemother. 2003 Apr;15(2):184-91 [12797397.001]
  • [Cites] Food Chem Toxicol. 2003 Nov;41(11):1433-46 [12962995.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1102-7 [12966433.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2439-49 [14602130.001]
  • [Cites] Int J Cancer. 2004 Apr 10;109(3):449-54 [14961586.001]
  • [Cites] Pharmacol Rev. 2004 Jun;56(2):185-229 [15169927.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1466-71 [15381937.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Natl Cancer Inst. 1986 Nov;77(5):1053-62 [3464797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 May;85(10):3585-9 [2897122.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):305-12 [1988577.001]
  • [Cites] Anticancer Res. 1995 Mar-Apr;15(2):495-501 [7763029.001]
  • [Cites] Int J Cancer. 1995 Oct 9;63(2):169-75 [7591199.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1897-905 [9164200.001]
  • [Cites] Nutr Cancer. 1997;28(1):63-73 [9200152.001]
  • [Cites] Lipids. 1997 Jul;32(7):697-705 [9252957.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):578-83 [9466659.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1091-7 [10091793.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):440-8 [10507768.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):585-90 [10521790.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1401-8 [15735116.001]
  • [Cites] Nutr Cancer. 2005;51(2):178-83 [15860440.001]
  • [Cites] Eur J Cancer Prev. 2005 Jun;14(3):263-70 [15901996.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 2005 Jul-Aug;29(4):236-40 [15961678.001]
  • [Cites] Free Radic Biol Med. 2005 Sep 15;39(6):742-51 [16109304.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6 Suppl):1467S-1476S [16841856.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2006 Sep;75(3):161-8 [16828546.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2006 Sep;75(3):183-90 [16837179.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7146-54 [18056195.001]
  • (PMID = 19920822.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 25167-62-8 / Docosahexaenoic Acids
  • [Other-IDs] NLM/ PMC2779856
  •  go-up   go-down


2. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van Veldhuizen PJ Jr, Quinn DI, Vogelzang NJ, Thompson IM Jr, Hussain MH: Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res; 2010 Jun 01;16(11):3028-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.
  • PURPOSE: Interleukin-6 (IL-6) facilitates cancer cell survival via pleotrophic effects.
  • We conducted a multicenter phase II study of CNTO328 (siltuximab) as second-line therapy for men with castration-resistant prostate cancer.
  • EXPERIMENTAL DESIGN: Eligible men had castration-resistant prostate cancer treated with one prior chemotherapy.
  • Accrual was planned in two stages, with 20 eligible patients in the first stage and 40 overall.
  • Plasma cytokines and growth factors were measured by Luminex.
  • RESULTS: Fifty-three eligible subjects had all received prior taxane therapy.
  • After treatment, IL-6 levels were >250-fold higher.
  • Thirty-two of 38 patients had a decline in C-reactive protein plasma levels at 6 weeks.
  • Declining C-reactive protein levels during treatment may reflect biological activity.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Castration. Drug Resistance, Neoplasm. Humans. Interleukin-6 / antagonists & inhibitors. Male. Middle Aged. Retreatment

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2702-6 [10914713.001]
  • [Cites] Cytometry B Clin Cytom. 2009 May;76(3):159-68 [18823005.001]
  • [Cites] Prostate. 2001 Jun 15;48(1):47-53 [11391686.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1773-81 [11410519.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] Circulation. 2002 Apr 23;105(16):1890-6 [11997273.001]
  • [Cites] Anesth Analg. 2003 Apr;96(4):1096-103, table of contents [12651667.001]
  • [Cites] BJU Int. 2003 Apr;91(6):545-53 [12656913.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):253-9 [15368468.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4633-9 [7553641.001]
  • [Cites] Cancer Res. 1997 Jan 1;57(1):141-6 [8988055.001]
  • [Cites] J Urol. 1999 Jan;161(1):182-7 [10037394.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):481-95 [15563311.001]
  • [Cites] Clin Exp Metastasis. 2004;21(5):399-408 [15672864.001]
  • [Cites] Oncology. 2005;68(1):2-9 [15741753.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2828-35 [16782921.001]
  • [Cites] Biochim Biophys Acta. 2006 Sep;1762(9):811-8 [16934957.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5578-86 [17000695.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Oncogene. 2007 May 3;26(20):2822-32 [17072336.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):556-63 [17577218.001]
  • [Cites] Int J Cancer. 2008 Apr 1;122(7):1521-9 [18027847.001]
  • [Cites] Urol Int. 2008;80(2):129-33 [18362480.001]
  • [Cites] Cancer Biol Ther. 2008 Jan;7(1):15-20 [18059178.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3251-5 [19447877.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2772-8 [19349545.001]
  • [Cites] Prostate. 2009 Aug 1;69(11):1245-55 [19444819.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5431-8 [19805692.001]
  • [Cites] Eur J Biochem. 2001 Jan;268(1):160-7 [11121117.001]
  • [Cites] Prostate. 2008 Jun 15;68(9):919-23 [18409189.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Mar;41(3):603-14 [18692155.001]
  • [Cites] Prostate. 2009 Apr 1;69(5):528-37 [19143022.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):155-69 [19011039.001]
  • [Cites] Mol Cancer Ther. 2009 Mar;8(3):665-71 [19240160.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2941-9 [19318561.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • (PMID = 20484019.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA035431-25; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / P30 CA093373; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / U10 CA014028-34; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / U10 CA027057-28S1; United States / NCI NIH HHS / CA / U10 CA042777-21; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / U10 CA012644-32; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / U10 CA063845; United States / NCI NIH HHS / CA / CA45441; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA020319-32; United States / NCI NIH HHS / CA / U10 CA045560-20; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA180835; United States / NCI NIH HHS / CA / U10 CA063845-09S4; United States / NCI NIH HHS / CA / U10 CA035119-24; United States / NCI NIH HHS / CA / U10 CA063848-16; United States / NCI NIH HHS / CA / CA63845; United States / NCI NIH HHS / CA / U10 CA014028; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / U10 CA063848; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / U10 CA045808-23; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046282-21; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA067575-14; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA058882-15; United States / NCI NIH HHS / CA / U10 CA011083-41; United States / NCI NIH HHS / CA / CA3981; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / UG1 CA189808; United States / NCI NIH HHS / CA / U10 CA045377-23; United States / NCI NIH HHS / CA / U10 CA022433-26S1; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Interleukin-6; 0 / siltuximab
  • [Other-IDs] NLM/ NIHMS197179; NLM/ PMC2898710
  •  go-up   go-down


3. Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH: Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol; 2009 Dec 10;27(35):6006-11
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
  • PURPOSE: To investigate the efficacy and safety of bevacizumab plus cisplatin and etoposide in patients with extensive-stage disease, small-cell lung cancer (ED-SCLC).
  • PATIENTS AND METHODS: In this phase II trial, 63 patients were treated with bevacizumab 15 mg/kg plus cisplatin 60 mg/m(2) and etoposide 120 mg/m(2), which was followed by bevacizumab alone until death or disease progression occurred.
  • Correlative studies were performed to explore the relationship between baseline and changes in plasma vascular endothelial growth factor (VEGF), soluble cell adhesion molecules (ie, vascular cell adhesion molecule [VCAM], intercellular cell adhesion molecule [ICAM], and E-selectin) and basic fibroblast growth factor and outcome.
  • CONCLUSION: The addition of bevacizumab to cisplatin and etoposide in patients with ED-SCLC results in improved PFS and OS relative to historical controls who received this chemotherapy regimen without bevacizumab.
  • This regimen appears to be well tolerated and has minimal increase in toxicities compared with chemotherapy alone.
  • Baseline VCAM levels predicted survival, but no other relationships among treatment, biomarkers, and outcome were identified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Small Cell Lung Carcinoma / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biomarkers / blood. Cisplatin / administration & dosage. Disease-Free Survival. E-Selectin / blood. Etoposide / administration & dosage. Female. Fibroblast Growth Factor 2 / blood. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Risk Assessment. Time Factors. Treatment Outcome. United States. Vascular Cell Adhesion Molecule-1 / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2114-22 [11304763.001]
  • [Cites] J Thorac Oncol. 2009 Dec;4(12):1555-60 [19875975.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1105-10 [12048093.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):4039-43 [12553029.001]
  • [Cites] Korean J Intern Med. 2004 Mar;19(1):48-52 [15053044.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2184-91 [15169807.001]
  • [Cites] Biometrics. 1985 Sep;41(3):741-4 [4074823.001]
  • [Cites] J Clin Oncol. 1987 Dec;5(12):1880-9 [2824710.001]
  • [Cites] J Natl Cancer Inst. 1991 Jun 19;83(12):855-61 [1648142.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):282-91 [1310103.001]
  • [Cites] Immunology. 1992 Dec;77(4):543-9 [1283598.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):647-58; discussion 661-3 [9597676.001]
  • [Cites] Int J Oncol. 1999 Jan;14(1):71-7 [9863011.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):324S-339S [17873178.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1407-12 [18316562.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1405-12 [19224857.001]
  • [Cites] Eur J Cancer. 2001 Dec;37(18):2392-7 [11720833.001]
  • (PMID = 19826110.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA07190; United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / CA49957; United States / NCI NIH HHS / CA / U10 CA014548; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / U10 CA007190; United States / NCI NIH HHS / CA / U10 CA049957; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / CA23318
  • [Publication-type] Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers; 0 / E-Selectin; 0 / VEGFA protein, human; 0 / Vascular Cell Adhesion Molecule-1; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; 2S9ZZM9Q9V / Bevacizumab; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2793043
  •  go-up   go-down


Advertisement
4. Pallarés C, Capdevila J, Paredes A, Farré N, Ciria JP, Membrive I, Basterrechea L, Gomez-Segura G, Barnadas A: Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Lung Cancer; 2007 Nov;58(2):238-45
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
  • PURPOSE: We conducted a prospective phase II trial to evaluate the efficacy and toxicity of induction chemotherapy with paclitaxel plus carboplatin followed by concurrent radiotherapy with weekly paclitaxel in stage IIIB non-small-cell lung cancer (NSCLC) patients.
  • PATIENTS AND METHODS: Patients with stage IIIB NSCLC received two 3-week cycles of paclitaxel 200mg/m(2) combined with carboplatin (target area under the plasma concentration curve (AUC) of 6 mg/ml) followed by weekly paclitaxel 50mg/m(2) concurrently with radiotherapy consisted of 2 Gy daily, 5 days per week (60 Gy total dose in 6 weeks).
  • Ninety percent of patients completed the planned treatment schedule.
  • The median overall survival time was 15 months and the 1-year, 2-year and 5-year overall survival rates were 57, 33 and 24%, respectively.
  • CONCLUSIONS: Induction chemotherapy with carboplatin and paclitaxel followed by weekly paclitaxel with concurrent radiotherapy was found to be active and tolerable in selected stage IIIB NSCLC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease Progression. Drug-Related Side Effects and Adverse Reactions. Humans. Middle Aged. Neoplasm Staging. Patient Compliance. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17658655.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Fujii T, Kunikane H, Okamoto H, Watanabe K, Kunitoh H, Mori K, Yokoyama A, Fukuda H, Tamura T, Saijo N: A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510. Jpn J Clin Oncol; 2009 Dec;39(12):784-90
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.
  • OBJECTIVE: It is important to find optimal regimens of cisplatin (CDDP)-based third-generation chemotherapy and radiotherapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC).
  • METHODS: This Phase II study was designed to determine the toxicity and efficacy of two courses of chemotherapy (CDDP 80 mg/m(2) on day 1 and irinotecan 60 mg/m(2) on days 1 and 8) followed by accelerated hyperfractionated thoracic radiotherapy (60 Gy/40 fractions in 4 weeks) combined with daily carboplatin (CBDCA) administration.
  • CBDCA was administered at a target area under the plasma level-time curve of 0.4 x (24 h creatinine clearance + 25), according to Calvert's formula.
  • Seven patients were Stage IIIA and 19 were Stage IIIB.
  • There was one treatment-related death due to sepsis and pneumonia associated with Grade 4 neutropenia and diarrhea during chemotherapy.
  • Median survival time and 2-year survival were 16.4 months and 21.5%, respectively.
  • This study was designed with Simon's two-stage design, and the response rate did not meet the criteria to proceed to the second stage and the study was terminated early.
  • CONCLUSIONS: This regimen might be inactive for patients with unresectable Stage III NSCLC.
  • [MeSH-major] Carboplatin / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Remission Induction
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic. Antineoplastic Combined Chemotherapy Protocols. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770129.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Robert F, Busby E, Marques MB, Reynolds RE, Carey DE: Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer; 2003 Nov;42(2):237-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results.
  • This report describes the preliminary results of a phase II study using docetaxel plus enoxaparin in 15 patients with stage IV non-small cell lung cancer (NSCLC).
  • Time to progression was the primary endpoint.
  • The median time to progression was 5 months (range, 2 to >15 months).
  • Eleven patients had elevated D-dimer plasma levels prior to therapy, and seven of these patients with a response or stable disease had a significant decline of the D-dimer during therapy.
  • There were no consistent changes of the plasma levels of the angiogenic factors, except for transforming growth factor-beta-1 (TGF-beta1).
  • The median baseline level of TGF-beta1 prior to therapy was 34,867 pg/ml.
  • Twelve out of 13 patients who achieved a response or stable disease had a significant reduction of the TGF-beta1 levels during therapy.
  • Enoxaparin in combination with chemotherapy was safe and well tolerated in patients with advanced NSCLC.
  • This preliminary data suggests that enoxaparin may prolong the time to progression, and therefore justify the continuation of this trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Anticoagulants / administration & dosage. Anticoagulants / adverse effects. Disease Progression. Enoxaparin / administration & dosage. Enoxaparin / adverse effects. Female. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Metastasis. Neutropenia / chemically induced. Taxoids / administration & dosage. Taxoids / adverse effects. Transforming Growth Factor beta / analysis. Transforming Growth Factor beta1

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14568692.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Enoxaparin; 0 / TGFB1 protein, human; 0 / Taxoids; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 15H5577CQD / docetaxel
  •  go-up   go-down


7. Liu TY, Chen SU, Kuo SH, Cheng AL, Lin CW: E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response. Mod Pathol; 2010 Nov;23(11):1507-17
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response.
  • Extranodal marginal-zone lymphoma of mucosa-associated lymphoid tissue of the stomach (gastric MALT lymphoma) is derived from memory B cells of the marginal zone.
  • Normal memory B cells do not express markers of germinal-center B cells, such as E2A (immunoglobulin enhancer-binding factor E12/E47), B-cell chronic lymphocytic leukemia/lymphoma 6 (BCL6), or activation-induced cytidine deaminase (AID).
  • E2A is a transcription factor that induces somatic hypermutations and blocks plasma cell differentiation.
  • In 50 stage-I(E)/II(E1) gastric MALT lymphomas, we confirmed that all cases were BCL6(-)/AID(-), but a subset (50%, 25/50) was E2A(+).
  • Clinically, E2A(+) gastric MALT lymphomas were more likely to spread to perigastric lymph nodes and were less responsive to Helicobacter eradication therapy than were E2A(-) gastric MALT lymphomas.
  • A prospective study would be necessary to verify the association between E2A expression and a poor response to Helicobacter eradication therapy.
  • [MeSH-major] B-Lymphocytes / chemistry. Basic Helix-Loop-Helix Transcription Factors / analysis. Biomarkers, Tumor / analysis. Immunologic Memory. Lymph Nodes / chemistry. Lymphoma, B-Cell, Marginal Zone / chemistry. MicroRNAs / analysis. Plasma Cells / chemistry. Stomach Neoplasms / chemistry
  • [MeSH-minor] Biopsy. Cell Differentiation. Cluster Analysis. Cytidine Deaminase / analysis. DNA-Binding Proteins / analysis. Gene Expression Regulation, Neoplastic. Genes, Immunoglobulin Heavy Chain. Helicobacter Infections / drug therapy. Helicobacter Infections / microbiology. Helicobacter pylori / pathogenicity. Humans. Immunohistochemistry. Mutation. Neoplasm Staging. Proto-Oncogene Proteins / analysis. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Taiwan. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802470.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / MIRN223 microRNA, human; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins; 0 / TCF3 protein, human; 0 / TCL1A protein, human; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


8. Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, Lo YM: Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer; 2003 Jul 15;98(2):288-91
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
  • BACKGROUND: Patients with International Union Against Cancer (UICC) Stage I-II nasopharyngeal carcinoma (NPC) appear to have a relatively favorable prognosis and generally are excluded from trials of combined modality treatment.
  • More recently, plasma/serum cell-free Epstein-Barr virus (EBV) DNA has been shown to be measurable in the majority of NPC patients at the time of diagnosis, and appears to have prognostic significance.
  • However, within Stage I-II disease, in which failure events are infrequent, the prognostic impact of the pretreatment EBV DNA level has not been addressed to our knowledge.
  • This issue has management implications because different therapeutic strategies currently are employed for patients with good-risk and those with poor-risk NPC.
  • METHODS: A cohort of 90 patients with UICC Stage I-II NPC (World Health Organization Grade 2/3 histology) had their pretherapy plasma/serum EBV DNA levels determined by a quantitative polymerase chain reaction assay and correlated with the probability of posttherapy failure.
  • All patients received radiation therapy only, except for three patients who also received concurrent chemotherapy.
  • Kaplan-Meier plots of the probability of locoregional failure, distant failure, and cancer-specific survival were compared with reference to clinical stage and EBV DNA levels.
  • RESULTS: With a median follow-up time of 45 months, 12 patients and 7 patients, respectively, had developed locoregional and distant failures, including 2 patients with both local and distant failures.
  • The probability of distant failure was significantly higher in patients with high (>4000 copies/mL plasma) compared with low EBV DNA levels (P=0.0001, log-rank test) and for Stage IIB disease compared with Stage I and Stage IIA disease combined (P=0.0149, log-rank test), but was not significantly different between patients with Stage II and those with Stage I disease.
  • Approximately 35% of patients with Stage IIB disease were in the at-risk group for distant failure, as identified by high EBV DNA levels.
  • CONCLUSIONS: Within a group of patients with UICC Stage I-II NPC, the pretherapy plasma EBV DNA level was found to identify a poor-risk group with a probability of distant failure similar to that of patients with advanced stage disease.
  • This group of patients may warrant management considerations currently applicable only to cases of Stage III-IV disease.
  • The prognostic significance of designating Stage IIB disease as per the 1997 UICC staging was confirmed, although the pretherapy EBV DNA level appears to be a more powerful prognostic discriminator in patients with early-stage NPC.
  • [MeSH-minor] Humans. Neoplasm Metastasis. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12872347.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


9. Osterborg A, Henriksson L, Mellstedt H: Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma. Acta Oncol; 2000;39(7):797-800
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
  • Idiotypic structures expressed on the myeloma immunoglobulin (Ig) protein (M-component) might be regarded as tumor-specific antigens.
  • Naturally occurring, idiotype-specific type I T-cell immunity has been observed preferentially in patients with early stage myeloma.
  • The idiotypic structures on the clonal myeloma B-cells (B lymphocytes and plasma cells) may serve as targets for active immunization.
  • Vaccination using the autologous monoclonal Ig as a vaccine has conferred resistance to tumor cell challenge in murine myeloma.
  • The autologous myeloma Ig protein was used for immunization in patients with progressive stage I and early stage II multiple myeloma.
  • When the idiotype (emulsified in aluminium phosphate) was used alone for immunization, a weak and transient idiotype-specific T-cell response was observed with no clinical effects.
  • In all five patients, a specific T-cell response was induced consisting preferentially of MHC class I restricted (CD8+) T-cells.
  • These results indicate that idiotype-specific T-cell immunity may be induced or enhanced by idiotype Ig vaccination in patients with early stage multiple myeloma, in which the tumor load is relatively low and the immune system is functionally less compromized than in patients with chemotherapy-treated, advanced stages of the disease.
  • The use of GM-CSF seems to be mandatory for the frequency and magnitude of the induced T-cell response.
  • [MeSH-major] Immunoglobulin Idiotypes / immunology. Multiple Myeloma / immunology. Myeloma Proteins / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Clone Cells. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Neoplasm Staging. Vaccination

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11145435.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Immunoglobulin Idiotypes; 0 / Myeloma Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


10. Menssen HD, Sakalová A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD: Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol; 2002 May 1;20(9):2353-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.
  • PURPOSE: Bisphosphonates have been found to reduce the incidence of skeletal-related events (SREs) in patients with multiple myeloma.
  • This is the first double-blind, randomized, placebo-controlled study to assess the efficacy of ibandronate, a third-generation amino-bisphosphonate, in preventing SREs in advanced-stage multiple myeloma patients.
  • PATIENTS AND METHODS: Patients with multiple myeloma stage II or III were randomly assigned to receive either ibandronate 2 mg or placebo as a monthly intravenous (IV) bolus injection for 12 to 24 months in addition to conventional chemotherapy.
  • RESULTS: Ninety-nine patients per treatment group were assessable for efficacy analysis.
  • The occurrence of SRE per patient year and the time to first SRE were not significantly different between the two treatment groups.
  • In overall evaluation, no differences were found between the treatment groups regarding bone pain, analgesic drug use, quality of life, and median survival (33.1 v 28.2 months, respectively).
  • Explorative post hoc analyses revealed that ibandronate patients with strongly suppressed bone-turnover markers (> or = 30% and > or = 50% mean reduction of serum osteocalcin and urinary C-terminal telopeptides) developed significantly less bone morbidity.
  • Ibandronate was tolerated well during as many as 25 therapy cycles.
  • CONCLUSION: Monthly injections of ibandronate 2 mg IV neither reduced bone morbidity nor prolonged survival in the overall population of stage II/III multiple myeloma patients.
  • [MeSH-major] Diphosphonates / therapeutic use. Multiple Myeloma / complications. Multiple Myeloma / drug therapy
  • [MeSH-minor] Bone Resorption / etiology. Bone Resorption / prevention & control. Chi-Square Distribution. Double-Blind Method. Female. Fractures, Bone / etiology. Fractures, Bone / prevention & control. Humans. Hypercalcemia / etiology. Hypercalcemia / prevention & control. Injections, Intravenous. Male. Middle Aged. Pain / etiology. Pain / prevention & control. Spinal Cord Compression / etiology. Spinal Cord Compression / prevention & control. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981007.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  •  go-up   go-down


11. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN Jr, Davies AM, Gandara DR: EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol; 2009 Dec;4(12):1466-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
  • PURPOSE: Activating mutations in the epidermal growth factor receptor (EGFR) are associated with enhanced response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), whereas KRAS mutations translate into poor patient outcomes.
  • We hypothesized that analysis of plasma for EGFR and KRAS mutations from shed tumor DNA would have clinical utility.
  • METHODS: An allele-specific polymerase chain reaction assay using Scorpion-amplification refractory mutation system (DxS, Ltd) was used to detect mutations in plasma DNA from patients with advanced stage NSCLC treated as second- or third-line therapy on a phase I/II trial of docetaxel plus intercalated erlotinib.
  • Six (12%) had single activating mutations in EGFR, associated with improved progression-free survival (median, 18.3 months), compared with all other patients (median, 3.9 months; p = 0.008), or those with wild-type EGFR (median, 4.0 months; p = 0.012).
  • All CR patients had E19del detectable in both tumor and plasma.
  • CONCLUSIONS: Activating EGFR mutations detected in shed DNA in plasma are significantly associated with favorable outcomes in patients with advanced NSCLC receiving docetaxel plus intercalated erlotinib.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884861.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA093373; United States / NCI NIH HHS / CA / P30 CA93373
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


12. Soo RA, Wang LZ, Tham LS, Yong WP, Boyer M, Lim HL, Lee HS, Millward M, Liang S, Beale P, Lee SC, Goh BC: A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol; 2006 Jul;17(7):1128-33
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
  • PATIENTS AND METHODS: Patients with chemonaive advanced non-small cell lung cancer (NSCLC) were randomised to receive gemcitabine at a fixed dose rate gemcitabine 750 mg/m(2) over 75 min (arm A) or gemcitabine 1000 mg/m(2) over 30 min (arm B) on days 1 and 8 every three week cycle.
  • Carboplatin at AUC of 5 was administered in both treatment arms on day 1 of each cycle.
  • End points were activity, tolerability and pharmacokinetics of plasma and intracellular gemcitabine.
  • Toxicity and quality of life scores were similar for both treatment arms.
  • Mean plasma Cmax(gemcitabine) and mean dFdCTP AUC in arm A was 20.8 microM +/- 17.2 microM and 35,079 +/- 18,216 microM*min respectively and in arm B, 41.2 +/- 13.9 microM and 32 249 +/- 11 267 microM*min respectively. dFdCTP saturation was reached in Arm B but not in Arm A.
  • However, this entails a longer infusion time with associated higher costs involved.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670205.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


13. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M, North American Brain Tumor Consortium: Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol; 2004 Nov 1;22(21):4282-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
  • This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas.
  • PATIENTS AND METHODS: Twenty-two patients with anaplastic gliomas (AG) and 23 patients with glioblastoma (GBM) whose tumors had recurred after radiotherapy and no more than two chemotherapy regimens were enrolled.
  • The trial was closed after the first stage because of the inadequate activity at the fenretinide doses used.
  • The first-administration mean plasma C(max) for fenretinide was 832 +/- 360 ng/mL at the 600 mg/m(2) bid dosage and 1,213 +/- 261 ng/mL at the 900 mg/m(2) bid dosage.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Arch Ophthalmol. 1986 Jan;104(1):69-70 [2935125.001]
  • [Cites] Clin Exp Dermatol. 1986 Nov;11(6):624-7 [2959409.001]
  • [Cites] Leuk Res. 1989;13(4):339-43 [2523991.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6149-52 [2529028.001]
  • [Cites] J Natl Cancer Inst. 1990 Jun 20;82(12):1063 [2140863.001]
  • [Cites] Eur J Cancer. 1991;27(2):138-41 [1827276.001]
  • [Cites] J Clin Pharmacol. 1992 Dec;32(12):1089-95 [1487546.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):2036-42 [8410127.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 19;86(2):138-40 [8271297.001]
  • [Cites] J Cell Biochem Suppl. 1993;17G:226-33 [8007703.001]
  • [Cites] Curr Opin Cell Biol. 1994 Dec;6(6):825-31 [7880529.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):36-9 [9020285.001]
  • [Cites] Tumori. 1997 Nov-Dec;83(6):884-94 [9526578.001]
  • [Cites] Arch Ophthalmol. 1998 Jun;116(6):759-63 [9639444.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):1931-5 [9816151.001]
  • [Cites] Mol Pharmacol. 1999 Mar;55(3):403-10 [10051523.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1138-46 [10393722.001]
  • [Cites] Int J Oncol. 1999 Sep;15(3):499-504 [10427131.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2230-5 [10473110.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1634-46 [11013380.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):419-30 [10690732.001]
  • [Cites] Drug Metab Dispos. 2000 Feb;28(2):205-8 [10640519.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2400-5 [12855611.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2032-9 [12796365.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):268-77 [12356357.001]
  • (PMID = 15514370.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCI NIH HHS / CA / U01 CA062426; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / R21 CA097767; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / M01-RR03186; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA16672; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01CA62421; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062405; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA62455; United States / NCI NIH HHS / CA / U01CA62399; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / R21 CA097767-02; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / CA097767-02; United States / NCRR NIH HHS / RR / M01 RR000042; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01 CA062422; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 187EJ7QEXL / Fenretinide
  • [Other-IDs] NLM/ NIHMS278296; NLM/ PMC3820102
  •  go-up   go-down


14. Schneider BJ, Worden FP, Gadgeel SM, Parchment RE, Hodges CM, Zwiebel J, Dunn RL, Wozniak AJ, Kraut MJ, Kalemkerian GP: Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs; 2009 Dec;27(6):571-8
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.
  • BACKGROUND: Alterations in retinoid signaling appear to be involved in the pathogenesis of small cell lung cancer (SCLC).
  • Since these data suggested that SCLC is the adult solid tumor that is most susceptible to fenretinide, a trial to evaluate the clinical activity of fenretinide in patients with SCLC was considered the definitive test of its clinical potential in adult oncology.
  • METHODS: Patients with progressive SCLC after one or two prior chemotherapy regimens and a performance status of 0-2 were eligible for the study.
  • Blood and saliva were collected pre-treatment and on day 7 of cycle 1 to measure fenretinide and retinol levels by high-pressure liquid chromatography (HPLC).
  • Fifteen patients had one prior chemotherapy regimen and four patients had two prior regimens.
  • The median time from diagnosis to enrollment was 10 months.
  • The median time to treatment failure was 5.7 weeks overall, while the four patients with stable disease demonstrated treatment failure at 11, 13, 19, and 52 weeks.
  • Median survival was 25 weeks, with one patient alive 22 months after the start of treatment.
  • The mean day 7 plasma fenretinide level was 2.90 +/- 1.66 μg/ml (7.40 +/- 4.25 muM; n = 14).
  • The mean pre-treatment and day 7 plasma retinol levels were 0.47 +/- 0.16 μg/ml and 0.05 +/- 0.07 μg/ml (n = 8), respectively.
  • The mean day 7 salivary fenretinide level was 0.08 +/- 0.18 μg/ml, with no correlation between salivary and plasma drug levels.
  • However, after the first stage of enrollment, the response rate did not meet criteria to proceed with full trial accrual.
  • Plasma concentrations of fenretinide that induce cytotoxicity in vitro in SCLC cell lines are clinically achievable, but there were no objective responses.
  • Non-invasive drug monitoring using saliva underestimates systemic exposure.
  • [MeSH-major] Fenretinide / therapeutic use. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Small Cell Lung Carcinoma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Survival Analysis. Time Factors. Treatment Outcome. Vitamin A / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 May 15;59(10):2493-8 [10344763.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49531-7 [12388538.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:80-6 [8747381.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):179-85 [15744595.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6149-52 [2529028.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4606-13 [14555536.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer Treat Rep. 1987 Apr;71(4):391-405 [3548957.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):6036-41 [8261419.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):2036-42 [8410127.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2032-9 [12796365.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1664-70 [11250995.001]
  • [Cites] Exp Cell Res. 1991 Jul;195(1):163-70 [1675998.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1345-55 [9607596.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4282-9 [15514370.001]
  • [Cites] Apoptosis. 2006 Oct;11(10):1677-94 [16850162.001]
  • [Cites] Leukemia. 2002 May;16(5):902-10 [11986953.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1794-801 [10561217.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):658-67 [10080612.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1674-80 [7473815.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1245-7 [8040893.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5603-10 [7585641.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] J Natl Cancer Inst. 1985 Nov;75(5):871-5 [2932587.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1914-9 [17035399.001]
  • [Cites] Int J Oncol. 1995 Sep;7(3):433-41 [21552857.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 1;96(17):1264-5 [15339958.001]
  • [Cites] Adv Pharmacol. 1995;33:315-47 [7495674.001]
  • [Cites] Cell Growth Differ. 1993 Oct;4(10):799-809 [8274449.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(2):145-50 [9923820.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1859-68 [1717924.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Mar;6(3):323-31 [18377850.001]
  • (PMID = 19225720.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11103-57-4 / Vitamin A; 187EJ7QEXL / Fenretinide
  •  go-up   go-down


15. Ławicki S, Czygier M, Omyła J, Bedkowska E, Szmitkowski M: [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients]. Pol Merkur Lekarski; 2007 Oct;23(136):259-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
  • Few clinical investigations have shown their autologous production both in vitro by human cell lines and in vivo by tumors.
  • AIM OF THE STUDY: We have investigated the plasma levels of G-CSF GM-CSF and CA 15-3 in breast cancer patients before and after surgery, and before and after chemotherapy.
  • MATERIAL AND METHODS: The plasma levels of cytokines were measured in 46 patients with breast cancer and in 30 healthy subjects.
  • RESULTS: G-CSF and GM-CSF plasma levels were significantly higher in II stage breast cancer patients before surgery comparing to the control group.
  • The plasma levels of tested cytokines were decreased after surgery, which suggested it's usefulness in evaluating breast cancer total resection.
  • Both of tested cytokines after chemotherapy were increased, which suggested secretion from damaged breast cancer cells.
  • Additionally we observed decreasing the plasma levels of cytokines, especially G-CSF in the 360th day after surgery.
  • In this study similar plasma levels of CA 15-3 were observed.
  • CONCLUSIONS: Tested cytokines, especially G-CSF, can be used in diagnostics and monitoring breast cancer therapy.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293847.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


16. Czygier M, Lawicki S, Stankiewicz I, Szmitkowski M: [Stem cell factor (SCF) in the plasma and phagocytic functions of granulocytes in breast cancer patients]. Przegl Lek; 2007;64(12):1014-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stem cell factor (SCF) in the plasma and phagocytic functions of granulocytes in breast cancer patients].
  • Stem Cell Factor (SCF) is a cytokine which stimulates the growth and development of primitive multipotential and unipotential hematopoietic stem cells in vitro and in vivo either alone or in combination with other cytokines such as Granulocyte-Macrophage Colony Stimulating Factor and Granulocyte Colony Stimulating Factor.
  • The patients were divided into two groups: A (stage I and II) and B (stage IV).
  • The blood for investigation was collected before and 30 days after surgery (group A) and before and in the course (12 week) of chemotherapy (group B), and from healthy subjects (control group).
  • SCF concentration was measured in the plasma, using a sensitive sandwich ELISA.
  • [MeSH-major] Breast Neoplasms / blood. Granulocytes / physiology. Stem Cell Factor / blood
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Phagocytosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595506.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Stem Cell Factor
  •  go-up   go-down


17. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E: Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer; 2008 Dec 16;99(12):2006-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
  • This randomised phase II study evaluated ASA404 plus standard therapy of carboplatin and paclitaxel in patients with histologically confirmed stage IIIb or IV non-small cell lung cancer (NSCLC) not previously treated with chemotherapy.
  • Patients were randomised to receive </=6 cycles of carboplatin area under the plasma concentration-time curve 6 mg ml(-1) min and paclitaxel 175 mg m(-2) (CP, n=36) or standard therapy plus ASA404 1200 mg m(-2) (ASA404-CP, n=37).
  • Safety profiles were similar and manageable in both groups, with most adverse effects attributed to standard therapy.
  • Tumour response rate (31 vs 22%), median time to tumour progression (5.4 vs 4.4 months) and median survival (14.0 vs 8.8 months, hazard ratio 0.73, 95% CI 0.39, 1.38) were improved in the ASA404 combination group compared with the standard therapy group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use. Xanthones / therapeutic use
  • [MeSH-minor] Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7406-13 [17189413.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3408-16 [12067983.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1937-42 [12085190.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3826-40 [12228202.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):43-52 [12497205.001]
  • [Cites] Lancet Oncol. 2003 Mar;4(3):141-8 [12623359.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1160-7 [12698178.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1844-50 [12799625.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2815-22 [12807934.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4428-38 [14645433.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):96-100 [14734457.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):906-10 [14970872.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2184-91 [15169807.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(6):409-13 [1934244.001]
  • [Cites] Oncol Res. 1994;6(2):79-85 [7949468.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1204-9 [7779712.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1860-70 [7543559.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(6):541-6 [9118467.001]
  • [Cites] Oncol Res. 1997;9(2):55-60 [9167186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):905-8 [9845119.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):633-8 [9973211.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3304-7 [10416582.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):423-35 [15928673.001]
  • [Cites] Oncologist. 2005;10 Suppl 3:1-10 [16368866.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1776-84 [16551862.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Radiat Res. 2001 Nov;156(5 Pt 1):503-9 [11604063.001]
  • (PMID = 19078952.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Xanthones; 0829J8133H / vadimezan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2607218
  •  go-up   go-down


18. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ Jr, Rollins BJ: A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res; 2001 Jun;7(6):1590-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
  • PURPOSE: Flavopiridol is a potent cyclin-dependent kinase inhibitor with preclinical activity against non-small cell lung cancer (NSCLC), inhibiting tumor growth in vitro and in vivo by cytostatic and cytotoxic mechanisms.
  • A Phase II trial was conducted to determine the activity and toxicity of flavopiridol in untreated patients with metastatic NSCLC.
  • Plasma levels of flavopiridol were measured daily during the first two infusions to determine steady-state concentrations.
  • The mean +/- SD steady-state concentration of drug during the first infusion was 200 +/- 89.9 nM, sufficient for cytostatic effects in in vitro models.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cyclin-Dependent Kinases / antagonists & inhibitors. Flavonoids / therapeutic use. Lung Neoplasms / drug therapy. Piperidines / therapeutic use
  • [MeSH-minor] Aged. Disease Progression. Dose-Response Relationship, Drug. Enzyme Inhibitors / therapeutic use. Female. Gas Chromatography-Mass Spectrometry. Humans. Male. Middle Aged. Neoplasm Metastasis. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11410495.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA62490-07
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Piperidines; 45AD6X575G / alvocidib; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


19. Riva C, Lavieille JP, Schmerber S, Cuisnie O, Reyt E: Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. Int J Oncol; 2000 Sep;17(3):543-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
  • The objective of this phase II prospective study was to determine the efficacy and the toxicity of a new schedule of neoadjuvant chemotherapy in locally advanced squamous cell carcinomas of the head and neck (SCCHN).
  • Thirty-three patients were included in this study (13 stage III and 20 stage IV).
  • Six cycles of neoadjuvant chemotherapy were planned before definitive locoregional treatment.
  • One treatment-related death was observed after grade IV neutropenia at the fourth cycle.
  • The average peak plasma levels for the 6 courses of CDDP, 5-FU, dl-FA and mTHF were 4.9+/-0.76 microM, 4.1+/-0.54 microM, 29.1+/-2.4 microM and 4.8+/-0.31 microM respectively.
  • Therefore, the administration of the 3 drugs by a 24 h continuous i.v. infusion reached an efficient level for drug modulation.
  • This new weekly schedule is as active as other standard therapy in the disease but significantly less toxic as neoadjuvant chemotherapy in advanced untreated SCCHN.
  • With the low toxicities observed with this schedule, additional treatment (surgery and/or radiotherapy) is warranted to evaluate the impact on overall survival of SCCHN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Chemotherapy, Adjuvant. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / pharmacokinetics. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / pharmacokinetics. Gastrointestinal Diseases / chemically induced. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leucovorin / pharmacokinetics. Life Tables. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Remission Induction. Risk Factors. Stomatitis / chemically induced. Survival Analysis. Thrombocytopenia / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10938396.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE: Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol; 2009 Aug 10;27(23):3808-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
  • PATIENTS AND METHODS: Previously untreated patients with asymptomatic Rai stage 0 to II CLL were eligible for participation.
  • Trough plasma EGCG levels were measured 1 month after initiation of therapy.
  • Other signs of clinical activity were also observed, with 11 patients (33%) having a sustained > or = 20% reduction in absolute lymphocyte count (ALC) and 11 (92%) of 12 patients with palpable adenopathy experiencing at least a 50% reduction in the sum of the products of all nodal areas during treatment.
  • Trough plasma EGCG levels after 1 month of treatment ranged from 2.9 to 3,974 ng/mL (median, 40.4 ng/mL).
  • A phase II trial to evaluate efficacy using 2,000 mg twice a day began in November 2007.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Catechin / analogs & derivatives. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Administration, Oral. Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Patient Selection. Tea. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2000 Mar 15;279(2):164-9 [10706785.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3807-17 [18599795.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):844-50 [11259102.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13322-30 [11278274.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:25-54 [11807163.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):381-5 [11809684.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):854-61 [11843819.001]
  • [Cites] Arch Pharm Res. 2002 Oct;25(5):561-71 [12433185.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):824-30 [12591733.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1466-71 [12697868.001]
  • [Cites] Curr Treat Options Oncol. 2003 Jun;4(3):211-8 [12718798.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3312-9 [12960117.001]
  • [Cites] Biochem Pharmacol. 2003 Nov 1;66(9):1769-78 [14563487.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7563-70 [14633667.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8118-21 [14678963.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1202-10 [14576043.001]
  • [Cites] Toxicol In Vitro. 2004 Oct;18(5):555-61 [15251172.001]
  • [Cites] Blood. 2004 Aug 1;104(3):788-94 [14996703.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1567-74 [15090467.001]
  • [Cites] Hematol Oncol. 1988 Jan-Mar;6(1):7-12 [3277904.001]
  • [Cites] Br J Haematol. 1989 Jun;72(2):141-9 [2757960.001]
  • [Cites] Mayo Clin Proc. 1994 Apr;69(4):323-8 [8170175.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):393-9 [7655336.001]
  • [Cites] Leukemia. 1996 Mar;10(3):456-9 [8642861.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):134-5 [9296488.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 17;89(24):1881-6 [9414176.001]
  • [Cites] Leuk Lymphoma. 1997 Nov;27(5-6):523-32 [9477135.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 19;249(2):391-6 [9712707.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2059-64 [15781612.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4627-33 [15958649.001]
  • [Cites] Leuk Res. 2006 Jun;30(6):707-12 [16325256.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1227-38 [16731755.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):435-47 [16983131.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2804-10 [16809610.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):223S-228S [17182830.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2144-50 [17404098.001]
  • [Cites] J Cell Physiol. 2007 Oct;213(1):252-60 [17477351.001]
  • [Cites] Life Sci. 2007 Jul 26;81(7):519-33 [17655876.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):395-402 [17686632.001]
  • [Cites] Blood. 2008 Jan 15;111(2):846-55 [17928528.001]
  • [Cites] J Cell Biochem. 2008 Feb 1;103(2):509-19 [17570133.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):537-46 [18275431.001]
  • [Cites] Antioxid Redox Signal. 2008 Mar;10(3):475-510 [18154485.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1923-30 [18577710.001]
  • [Cites] Cancer Lett. 2008 Oct 8;269(2):269-80 [18501505.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1830-8 [11251015.001]
  • (PMID = 19470922.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / R01 CA136591; United States / NCI NIH HHS / CA / CA113408; United States / NCI NIH HHS / CA / CA6912
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Tea; 0 / polyphenon E; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  • [Other-IDs] NLM/ PMC2727287
  •  go-up   go-down


21. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M: A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol; 2008 Apr;3(4):386-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
  • INTRODUCTION: Vandetanib (ZACTIMA) is a once-daily, oral anticancer drug that selectively inhibits vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling.
  • PATIENTS AND METHODS: Eligible patients with locally advanced or metastatic (stage IIIB/IV) or recurrent non-small cell lung cancer, previously treated with chemotherapy, were randomized to receive once-daily oral vandetanib 100, 200, or 300 mg (1:1:1).
  • Baseline plasma VEGF levels appeared to be lower in patients who experienced clinical benefit after vandetanib treatment.
  • CONCLUSION: In Japanese patients with advanced non-small cell lung cancer, vandetanib monotherapy (100-300 mg/d) demonstrated antitumor activity with an acceptable safety and tolerability profile.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperidines / administration & dosage. Quinazolines / administration & dosage
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Administration, Oral. Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / secondary. Double-Blind Method. Female. Humans. Japan / epidemiology. Male. Maximum Tolerated Dose. Middle Aged. Mutation / genetics. Prognosis. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379357.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


22. White SC, Lorigan P, Margison GP, Margison JM, Martin F, Thatcher N, Anderson H, Ranson M: Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer; 2006 Oct 9;95(7):822-8
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer.
  • To determine the efficacy and tolerability of SPI-77 (sterically stabilised liposomal cisplatin) at three dose levels in patients with advanced non-small-cell lung cancer (NSCLC).
  • Patients had Stage IIIB or IV NSCLC and were chemo-naïve, and Eastern Oncology Cooperative Group 0-2.
  • The pharmacokinetic profile of SPI-77 was typical for a liposomally formulated drug, and the AUC appeared to be proportional to the dose of SPI-77.
  • Plasma Pt levels and leucocyte DNA adduct levels did not appear to rise with successive doses.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Area Under Curve. DNA Adducts / metabolism. Dose-Response Relationship, Drug. Female. Half-Life. Humans. Leukocytes / drug effects. Male. Metabolic Clearance Rate. Middle Aged. Neoplasm Staging. Platinum / blood. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jan;18(1):122-30 [10623702.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(1):1-7 [9923534.001]
  • [Cites] Lung Cancer. 2001 Dec;34(3):427-32 [11714540.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Mar;49(3):201-10 [11935212.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):343-9 [12201498.001]
  • [Cites] Cancer. 1977 Apr;39(4):1397-402 [856438.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Nov;18(11):1069-74 [6891650.001]
  • [Cites] Drug Intell Clin Pharm. 1985 May;19(5):362-7 [3891281.001]
  • [Cites] Cancer. 1985 Oct 15;56(8):1934-9 [4040801.001]
  • [Cites] J Nucl Med. 1996 Feb;37(2):326-32 [8667071.001]
  • [Cites] Anticancer Drugs. 1996 Jun;7(4):483-8 [8826617.001]
  • [Cites] J Pharm Sci. 1996 Aug;85(8):824-7 [8863271.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;39(1-2):131-7 [8995510.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3185-91 [9336354.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2459-65 [9667264.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1131-2 [9849467.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):493-6 [11398881.001]
  • (PMID = 16969346.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Adducts; 0 / SPI-77, liposomal; 0 / cisplatin-DNA adduct; 49DFR088MY / Platinum; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2360546
  •  go-up   go-down


23. Soo RA, Lim HL, Wang LZ, Lee HS, Millward MJ, Tok LT, Lee SC, Lehnert M, Goh BC: Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study. Cancer Chemother Pharmacol; 2003 Aug;52(2):153-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
  • PURPOSE: To determine the maximally tolerated dose (MTD) of gemcitabine administered at a fixed dose-rate of 10 mg/m(2) per min in combination with fixed dose carboplatin, to evaluate the toxicity of this regimen and to determine the pharmacokinetics of plasma gemcitabine.
  • METHODS: Patients with advanced stage non-small-cell lung cancer (NSCLC) received carboplatin (AUC 5) on day 1 followed by gemcitabine at a fixed dose rate of 10 mg/m(2) per min in escalating durations of infusion on days 1 and 8 every 21 days.
  • Pharmacokinetic sampling was obtained on day 1, cycle 1 of treatment.
  • The recommended phase II dose of gemcitabine was 750 mg/m(2).
  • Plasma gemcitabine did not reach steady state except in one patient with the durations of infusion studied.
  • Plasma concentrations, however, were above 10 micro mol/l between 20 and 90 min in all patients.
  • Pharmacokinetic studies demonstrated that the target plasma gemcitabine concentration above 10 micro mol/l was achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Area Under Curve. Carboplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12750842.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


24. Xu L, Wang Y, Wu W, Yan H, Gao XD, Yu Q, Shen ZX, Mi JQ: [Clinical study of multiple myeloma: a report of 182 cases]. Zhonghua Yi Xue Za Zhi; 2010 Apr 13;90(14):972-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of multiple myeloma: a report of 182 cases].
  • OBJECTIVE: To explore the applicability of Durie Salmon (DS) and International Staging System (ISS) for Chinese patients with multiple myeloma (MM) and to evaluate the efficacy of major therapeutic options and the influence of various prognostic factors on survival were also evaluated.
  • METHODS: The patient survival was compared with regards to DS and ISS.
  • RESULTS: The median survival of patients with DS stages I, II and III were 79, 82 and 43 months, respectively.
  • There was no significance between stage I and II/III.
  • The median survival of patients with ISS stages I, II and III were 79, 49 and 43 months, respectively.
  • Multivariate analysis suggested that age, percentage of plasma cell in bone marrow, C-reactive protein (CRP) and beta2-microglobulin (2-MG) were independent prognostic factors for OS.
  • CONCLUSION: ISS is more applicable than DS, especially for low risk patients.
  • The efficacy of VAD-like regimen combined Thal as first-line treatment is proven to be reliable.
  • Induction therapy including thalidomide can not only improve the ORR, but also delay the relapse or progression of disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Multiple Myeloma / drug therapy. Multiple Myeloma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dexamethasone. Doxorubicin. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Thalidomide / therapeutic use. Treatment Outcome. Vincristine. Young Adult

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646647.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VAD I protocol
  •  go-up   go-down


25. Yamamoto N, Nishimura Y, Nakagawa K, Matsui K, Fukuoka M: Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer. Cancer Chemother Pharmacol; 2006 Sep;58(3):285-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.
  • PURPOSE: We conducted a phase I study to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLT) of weekly docetaxel and cisplatin (DOC/CDDP) with concurrent thoracic radiotherapy (TRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
  • TRT was given to a total dose of 60 Gy at 2 Gy per fraction over 6 weeks.
  • The patient characteristics were: PS 0/1/2, 6/13/2; Sq/Ad, 16/5; stage IIIA/IIIB, 4/17.
  • The median survival time was 23.1 months.
  • The main DLT was esophagitis, and it significantly correlated with the plasma AAG concentration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung. Lung Neoplasms
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Radiation Dosage. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / therapeutic use. Thorax. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416334.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Mohty AM, Grob JJ, Mohty M, Richard MA, Olive D, Gaugler B: Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. Immunobiology; 2010;215(2):113-23
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma.
  • This study investigated the immunomodulatory effects of low-dose interferon-alpha (IFN-alpha) in a cohort of 21 stage II or III melanoma patients treated in an adjuvant setting.
  • The impact of IFN-alpha was more marked at the level of all CD3+CD8+ T-cell subsets that showed a sustained and significant decrease.
  • Both myeloid and plasmacytoid dendritic cell (DC) subsets were depleted, but the MDC/PDC ratio tended to increase 12 months after treatment.
  • IP-10/CXCL10 plasma levels significantly increased already at 3 months of therapy and remained at significantly high levels during the study period.
  • Low-dose IFN-alpha therapy can significantly affect phenotypic and functional properties of blood circulating lymphocytes and antigen-presenting cells, and production of IP-10/CXCL10, that appear to be important for the orchestration of an effective immune response during adjuvant IFN-alpha therapy for melanoma.
  • [MeSH-major] Chemokine CXCL10 / blood. Immunomodulation. Interferon-alpha / administration & dosage. Melanoma / drug therapy. Polyethylene Glycols / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / therapeutic use. Adult. Aged. Antigens, CD3 / immunology. Cohort Studies. Female. France. Humans. Lymphocyte Count. Male. Middle Aged. Neoplasm Staging. Receptors, CXCR3 / immunology. Recombinant Proteins. T-Lymphocyte Subsets / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19450896.001).
  • [ISSN] 1878-3279
  • [Journal-full-title] Immunobiology
  • [ISO-abbreviation] Immunobiology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, CD3; 0 / CXCR3 protein, human; 0 / Chemokine CXCL10; 0 / Interferon-alpha; 0 / Receptors, CXCR3; 0 / Recombinant Proteins; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


27. Henk JM, Bishop K, Shepherd SF: Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol; 2003 Jan;66(1):65-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of head and neck cancer with CHART and nimorazole: phase II study.
  • BACKGROUND AND PURPOSE: Causes of failure of radiotherapy in squamous cell carcinoma of the head and neck probably include repopulation and hypoxia.
  • Very accelerated schedules such as continuous hyperfractionated accelerated radiation therapy (CHART) overcome the repopulation problem but allow limited time for reoxygenation, so a hypoxic-cell sensitizer may be especially beneficial.
  • METHODS: Sixty-one patients with advanced stage III (21) or IV (40) squamous cell carcinoma of the head and neck unsuitable for surgery were treated in a phase II study of the combination.
  • The radiation dose was 56.75 Gy in 36 fractions in 12 consecutive days.
  • This dosage consistently yielded plasma concentrations above 30 microg/ml.
  • RESULTS: All the patients have been followed for a minimum of 2 years since treatment.
  • Loco-regional control at 2 years is 55%, stage III 62% and stage IV 50%.
  • Normal tissue effects were the same as those previously seen with CHART, except for a possible slight increase in acute skin reaction.
  • Two patients developed grade 1 peripheral neuropathy, and one patient died during treatment of encephalopathy, which was probably an idiosyncratic reaction to the drug.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Nimorazole / administration & dosage
  • [MeSH-minor] Adult. Aged. Dose Fractionation. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care / methods. Prognosis. Radiation Dosage. Risk Assessment. Survival Analysis. Terminally Ill. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12559522.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 469ULX0H4G / Nimorazole
  •  go-up   go-down


28. Langevin AM, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, Chen Z, Adamson PC, Children's Oncology Group: A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Mar;50(3):577-80
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
  • BACKGROUND: Rebeccamycin Analogue (NSC #655649), a chemically synthesized glycosyl-dichloro-indolocarbazole derivative of rebeccamycin with topoisomerase inhibiting activity, has in vitro activity against pediatric tumor cell lines and tumor specimens including rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma and medulloblastoma.
  • PROCEDURE: The primary objective of this trial was to determine the response rate to Rebeccamycin analogue NSC #655649 in children with refractory solid and CNS tumors.
  • A two-stage design was used for this Phase II trial.
  • Rebeccamycin analogue, 650 mg/m(2), was administered every 21 days, and could be escalated to 780 mg/m(2) in subsequent cycles to achieve a maximum plasma drug concentration >5 microg/ml.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Diseases / chemically induced. Carbazoles. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug-Induced Liver Injury / etiology. Female. Glucosides. Humans. Infant. Infant, Newborn. Infusions, Intravenous. Male. Neoplasm Proteins / antagonists & inhibitors. Pancreatitis / chemically induced. Rhabdomyosarcoma / drug therapy. Salvage Therapy. Topoisomerase II Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17610262.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / P30CA-54174
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibiotics, Antineoplastic; 0 / Carbazoles; 0 / Glucosides; 0 / Neoplasm Proteins; 0 / Topoisomerase II Inhibitors; A60X6MBU6G / becatecarin
  •  go-up   go-down


29. Sakai C, Murotani N: [Adult T-cell leukemia/lymphoma in a patient on hemodialysis-resistance to CHOP, but unexpected effect and remission achieved by sobuzoxane alone]. Gan To Kagaku Ryoho; 2010 Feb;37(2):347-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult T-cell leukemia/lymphoma in a patient on hemodialysis-resistance to CHOP, but unexpected effect and remission achieved by sobuzoxane alone].
  • Computed tomography revealed several enlarged lymph nodes assembling at the left axilla.
  • The pathological diagnosis was peripheral T-cell lymphoma, CD4(+).
  • He was clinically diagnosed as having an adult T-cell leukemia/lymphoma, lymphoma type, and clinical stage II.
  • Two courses of CHOP therapy were given to the patient, without any response.
  • Because the patient had to undergo hemodialysis consistently, we preferred mild salvage therapy to more intensive treatment.
  • SBZ therapy, 800 mg/day x 3 days, was continued at intervals of 7 to 8 weeks until October 2008.
  • At the time of reporting, May 2009, the patient was well without recurrence of ATLL, and the remission has lasted 26 months or more.
  • The reason why CHOP-resistant ATLL responded dramatically to SBZ alone is not clear, but the plasma concentration of the metabolite of SBZ was possibly very high because of renal failure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Leukemia-Lymphoma, Adult T-Cell / complications. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Piperazines / therapeutic use. Renal Dialysis. Renal Insufficiency / complications
  • [MeSH-minor] Aged. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Remission Induction. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154500.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Piperazines; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; R1308VH37P / sobuzoxane; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


30. Ro JY, Shen SS, Lee HI, Hong EK, Lee YH, Cho NH, Jung SJ, Choi YJ, Ayala AG: Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol; 2008 May;32(5):752-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
  • In this report, we summarized the clinicopathologic features of 9 cases of plasmacytoid transitional cell carcinoma (TCC) of the urinary bladder, a rare variant of TCC.
  • Cystoscopic findings revealed a dominant solid mass with surrounding multiple papillary lesions in 6 cases and multiple masslike lesions in 3 other cases.
  • One patient had TNM stage I disease, 2 had stage II disease, 3 had stage III disease, and 3 had stage IV disease.
  • Four patients were treated by radical cystectomy with chemotherapy, 2 by radical cystectomy alone, 1 each by chemotherapy or intravesical bacillus Calmette-Guerin infusion alone, and 1 did not receive any further therapy.
  • Eight of 9 cases were associated with high-grade TCC, and transitional cell carcinoma in situ was present in 4 cases.
  • Interestingly, plasmacytoid transitional cell carcinoma in situ was noted in 1 case.
  • In summary, plasmacytoid TCC tends to present at an advanced stage and to have a poor prognosis.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Plasma Cells / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Cell Nucleus / pathology. Combined Modality Therapy. Cystoscopy. Cytoplasm / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379419.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


31. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, Chin S, Irish J, LaFramboise S, Oza AM: A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer; 2005 Mar;41(4):523-30
Hazardous Substances Data Bank. LOVASTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.
  • Squamous cell carcinomas of the head and neck (HNSCC) and of the cervix (CC) are particularly sensitive to the apoptotic effects of lovastatin in vitro.
  • This was a Phase I open-label study to determine the recommended Phase II dose (RPTD) of lovastatin in advanced HNSCC or CC.
  • Plasma samples were collected for pharmacokinetic analysis.
  • Biologically relevant plasma lovastatin levels were obtained.
  • One patient achieved SD and clinical benefit for 14 months on study and a further 23 months off treatment.
  • The disease stabilisation rate of 23% seen in these end-stage patients is encouraging.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage. Lovastatin / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737556.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 9LHU78OQFD / Lovastatin
  •  go-up   go-down


32. Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK, Latz JE, Schneck KB, Yuan Z, Sanchez-Torres JM: Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res; 2010 May 15;16(10):2872-80
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC.
  • EXPERIMENTAL DESIGN: Patients with TSF (pleural effusions, ascites) and relapsed, stage III/IV NSCLC or malignant pleural/peritoneal mesothelioma were treated with pemetrexed (500 mg/m2) on day 1 of each 21-day cycle.
  • TSF was drained at any time only if clinically indicated.
  • Plasma samples were collected during cycles 1 and 2 to compare pemetrexed concentrations with reference data from patients without TSF.
  • Seven grade 3/4 drug-related toxicities, including four hematologic, were reported; there were no treatment-related deaths.
  • There was no correlation between TSF amount and type, number, and sequelae of toxicities.
  • Pemetrexed plasma concentrations were within the range of those in patients without TSF.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Ascites / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / pharmacokinetics. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Adult. Aged. Humans. Lung Neoplasms / complications. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Middle Aged. Neoplasm Staging. Pemetrexed. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Pleural Neoplasms / complications. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR.
  • (PMID = 20460481.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down






Advertisement